Here is the motivation of the prize:
In her research, Emma Aneheim has developed a technology for targeted radiation therapy against cancer. The technology is based on so-called astatinated antibodies and Emma Aneheim has played a crucial role in developing an automated production platform for astatinated drugs in a reproducible, standardized and GMP-adapted way. The method forms the basis for a biotech company, Alpha Therapy Solutions AB. The company is now marketing a technology giving researchers across the world a tool for clinical trials with astatinated drugs.
Emma Aneheim has a master’s degree in chemical engineering and a PhD in nuclear chemistry from Chalmers University of Technology. She now holds a position at the Department of Radiation Physics, Sahlgrenska Academy, where her sphere of activities includes clinical studies of ovarian cancer treatment using her technology. Emma Aneheim is a good example of what can be achieved when high engineering competence and clinical problems meet in a fruitful collaboration across disciplines.